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INTRODUCTION
Multiple sclerosis (MS) is considered a prototypic organ-specific autoimmune disease. It mainly affects young adults and approximately 2.5 million people worldwide. Patients often develop impairments of visual, sensory, motor, neurocognitive, and autonomic functions. Its etiology involves a complex genetic trait with >100 quantitative trait loci (Beecham et al., 2013; Sawcer et al., 2011) , most importantly the HLA-DR15 haplotype, for which an association with MS has already been described in 1973 (Jersild et al., 1973) . Since HLA-class II molecules restrict CD4 + T cells, the genetic association provides a strong argument for the central role of adaptive immunity and CD4 + T cells in MS. Yet, how HLA-DR15 and other risk alleles induce and sustain MS is incompletely understood including the lack of an autoantigen unequivocally associated with MS pathogenesis. Epstein-Barr virus (EBV) infection, low vitamin D3, smoking, and obesity (Olsson et al., 2017) have been identified as environmental risk factors, and genes and environment likely act in concert to trigger an autoimmune reaction against CNS tissue (Dendrou et al., 2015; Sospedra and Martin, 2005) .
The vast majority of MS risk-conferring genes including HLA-DR15 are immune function related, while CNS-related genes are remarkably absent (Beecham et al., 2013; Sawcer et al., 2011) . Considering data from the animal model of MS, experimental autoimmune encephalitis (EAE) (Dendrou et al., 2015; Goverman, 2009; Sospedra and Martin, 2005) , there is now compelling evidence that MS is an autoimmune disease with dysregulated adaptive immunity at its core. Findings from EAE and blood cells of MS patients together with the strong genetic HLA-DR15 association hint at the importance of myelin-reactive CD4 + T cells (Sospedra and Martin, 2005) . However, characterization of CNS-infiltrating immune cell populations and experience from B cell-depleting therapies suggest that CD8 + T cells, proinflammatory B cells, and autoantibodies are likely also involved (Dendrou et al., 2015; Hauser et al., 2008; Li et al., 2015; Sospedra and Martin, 2005) . A central question is how disease-relevant T and B cells interact.
Starting from MS risk genes involved in T cell activation, differentiation, and homeostasis and the prominent role of HLA-DR15, we searched for experimental systems to approach this issue. The observation that myelin-specific T cell clones can be activated by antigen-presenting cells (APCs) in the absence of exogenous nominal antigen and the involvement of CD4, HLA-class II, and self-peptides provided the basis for such a system (Cai and Hafler, 2007; Kondo et al., 2001) . Further, in MS reduced thymic output of T cells (Duszczyszyn et al., 2006; Hug et al., 2003) , alterations in T regulatory cells (Carbone et al., 2014) , increased T cell proliferation and related signatures (Carbone et al., 2014; Tuller et al., 2013) , decreased autologous mixed lymhocyte reaction (AMLR) (Hafler et al., 1985) , and reduced T cell receptor (TCR) repertoire diversity (Laplaud et al., 2004; Muraro et al., 2005) indicate perturbed T cell homeostasis. In distinction to the defective AMLR, which was shown to be altered not only in MS, but also in other autoimmune diseases like rheumatoid arthritis already three decades ago (Kitas et al., 1988) and which remained unexplained, we recently showed that spontaneous in vitro T cell proliferation is increased in MS patients (Mohme et al., 2013) . We refer to this phenomenon as ''autoproliferation'' (AP). The HLA-DR15 haplotype and DR15-presented selfpeptides take part in this process (Mohme et al., 2013) , but which cells induce and maintain T cell proliferation and whether AP T cells may be pathogenic are unknown. Here, we characterized in detail the cellular interactions that lead to increased AP and provide evidence for its potential involvement in MS.
RESULTS

AP Increases during Remission
Based on the increased AP in MS patients using thymidine incorporation (Mohme et al., 2013) , we developed a carboxyfluorescein diacetate N-succinimidyl ester (CFSE)-labeling protocol, which allows characterization of AP (CFSE dim ) and non-proliferating (CFSE hi ) cell populations ( Figure 1A ) and correlates well with thymidine incorporation ( Figure S1A ). It is important to note that we cultured peripheral blood mononuclear cells (PBMCs) without stimulus and under serum-free conditions. With this assay, we examined AP in a first cohort of 32 healthy donors (HDs) and 50 untreated relapsing-remitting MS (RRMS, nihil) patients (Table S1 ). 24.1% of AP cells were B cells (CD19 + ), 43.6% T cells (CD3 + ), with a higher proportion of CD4 + than CD8 + T cells, and 32.3% unknown cells ( Figures  1B, 1C , S1B, and S1C). AP T cells showed an effector memory and highly activated phenotype with strong upregulation of surface HLA-DR with increasing cycles of division (Figures 1D and 1E) . Similar to our previous study (Mohme et al., 2013) , we confirmed a higher frequency of individuals with stronger AP in the MS group as compared to HDs and also to two other organ-specific autoimmune diseases, psoriasis or Crohn's disease ( Figure 1F ). Interestingly, when the AMLR was investigated in psoriasis and Crohn's disease, it also did not differ from HDs (Davidsen and Kristensen, 1986; Schopf et al., 1986) , while it is defective in MS (Hafler et al., 1985) .
Next, we explored the association between AP in HDs and RRMS disease stages, i.e., active (relapse; REL, nihil) or inactive (remission; REM, nihil). Interestingly, we observed higher frequencies of AP cells independent of the rounds of cell division in REM compared to HDs and REL, as well as increased frequencies of AP effector memory T cells in REM compared to HDs (Figures 1G, 1H , and S1D-S1G). We confirmed these results in a second cohort comparing AP with other methods of B or T cell activation in HDs and REM. In contrast to AP and a-immunoglobulin M (IgM) stimulation, T cell activation by a foreign recall antigen (tetanus toxoid), allogeneic mixed lymphocyte reaction (MLR) or phytohemagglutinin (PHA) did not differ between HDs and REM ( Figure S2A ).
HLA-DR-TCR Interactions Are Essential for AP
In line with our previous data (Mohme et al., 2013) , HLA-DR15 + HDs and REM showed increased AP ( Figure 1I ). Further, we now found that AP CD4 + but not CD8 + T cells are increased in HLA-DR15 + compared to HLA-DR15 À REM ( Figure 1J ). Given the multifactorial etiology of MS, we genotyped REM and HDs to examine 134 published non-HLA MS risk-associated SNPs (Beecham et al., 2013; Sawcer et al., 2011) and compared their effect to that of HLA-DR15 on AP. Probably due to the small sample size, our results do not support a significant contribution neither for single MS risk SNPs nor for a MS risk score derived from 102 of these risk variants, yet confirmed a significant association between HLA-DR15 and AP (Table S2 and Table S3 ).
The strong upregulation of HLA-DR on B cells during AP (Mohme et al., 2013) and the above association with the (C-E) CD4/CD8 ratio of T cells (C), naive/memory (D), and activated HLA-DR-expressing (E) CD4 + and CD8 + T cells in CFSE hi , CFSE mid , and CFSE low cells (n = 20 RRMS and HDs; in C and E, in D, mean) . T cell subsets: T naive CD45RA + CCR7 + ; T CM CD45RA -CCR7 + ; T EM CD45RA -CCR7 -; T TEMRA CD45RA + CCR7 -. (F) AP of HDs (n = 32) and untreated patients with RRMS (n = 50), psoriasis (n = 10), and Crohn's disease (CD; n = 7) (mean ± SEM). (G and H) Frequency of all (CFSE dim ) (G) or only high (CFSE low ) (H) AP cells for HDs (n = 32), untreated RRMS patients in relapse (REL; n = 18) or remission (REM; n = 32) (mean ± SEM; Kruskal-Wallis test). (I) AP in HLA-DR15 À and DR15 + HDs (n = 32), REL (n = 18), and REM (n = 32) (mean ± SEM; Kruskal-Wallis test). (J) Frequency of AP CD4 + and CD8 + T cells in HLA-DR15 À (n = 15) and DR15 + (n = 17) REM (mean ± SEM; Mann-Whitney U test).
Figure 2. AP Involves Classical and Non-classical Th1 Cells with Increased Proinflammatory Responses in MS
(A) AP (% CFSE dim ) and cytokine secretion profile for each donor (n = 32 HDs; n = 32 REM) after 7-day culture. Subject values are organized according to their AP strength. The graphs under the heatmap represent the mean cytokine secretion in supernatants (mean ± SEM; Mann-Whitney U test). (B) Mean cytokine response following AP in the presence of blocking HLA-DR, CD4, or isotype controls (n = 5 REM). (C) Intracellular IFN-g and phosphorylation of STAT1 in CFSE hi and CFSE dim (AP) T cells. Representative example out of 5 REM. (D) Proportion of CD4 and CD8 subsets in AP IFN-g + T cells (mean ± SEM; n = 5 REM; Mann-Whitney U test).
(legend continued on next page) HLA-DR15 haplotype indicated that interactions between HLA-DR on B cells and TCR/CD4 on T cells might be involved in AP. This was confirmed by the strong inhibitory effects of antibody blocking of both HLA-DR as reported previously (Mohme et al., 2013) , but also of CD4 ( Figure 1K ). Phosphorylation of the TCRassociated CD3 zeta chain (CD3z) and the CD3 zeta chain-associated protein 70 (ZAP-70) in AP T cells ( Figure 1L ) as well as the involvement of lymphocyte-specific protein tyrosine kinase (LCK) ( Figure 1M) show that TCR and self-peptide/HLA-class II interactions participate in inducing and/or sustaining AP.
Classical and Non-classical Th1 Cells Are Involved in AP Next, we addressed which functional phenotypes are involved in increased AP in REM. Culture supernatants after AP contained particularly high amounts of interferon (IFN)-g, increased interleukin-2 (IL-2), IL-13, IL-21, and granulocytemacrophage colony-stimulating factor (GM-CSF) in REM compared to HDs and either low or absent . In contrast to AP, IFN-g secretion upon activation with conventional T cell stimuli did not differ between HDs and REM ( Figure S2B ). IFN-g correlated best with AP ( Figure 2A ) and was higher in HLA-DR15 + individuals ( Figure S2C ). Cytokines dropped after blocking either HLA-DR or CD4, whereas in vitro neutralization of IFN-g and GM-CSF did not inhibit AP indicating that cytokine production is a consequence of AP (Figures 2B and S2D) .
Intracellular cytokine staining confirmed that AP CD4 + T cells mainly express IFN-g and, consistent with a Th1 phenotype, also show STAT1 signaling ( Figures 2C and 2D ). The predominant proinflammatory Th1-like phenotype in AP CD4 + T cells of REM is supported by RNA sequencing, which shows significant upregulation of Th1-specific markers such as TBX21 (T-bet), CXCR3, and IFNG (Figure 2E ). Th2 and Th17 markers such as GATA3, IL4 or RORC, and IL17A were absent or not differentially expressed, but other Th17-specific markers such as AHR and BATF as well as CSF2 (GM-CSF) were upregulated. In line with these findings, we observed high frequencies of CXCR3 + CD4 + T cells expressing the Th17-associated chemokine receptor CCR6 in the AP compartment ( Figure 2F ), referred to as nonclassical Th1 cells (i.e., Th1/Th17 or exTh17-Th1) (Geginat et al., 2013) . These cells were shown to be polyfunctional and increased in MS (Paroni et al., 2017) , and both chemokine receptors, CXCR3 and CCR6, are involved in brain homing of T cells (Balashov et al., 1999; Reboldi et al., 2009) . Consistent with in vivo results (Basdeo et al., 2017) , we observed higher AP in classical and non-classical Th1 cells ( Figure 2F ). Whether expression of Th17-specific markers and GM-CSF marks a distinct T helper cell subset (Geginat et al., 2013; Hartmann et al., 2014) originating from Th17 cells or is part of pathogenic Th1 differentiation is currently not clear, but our findings under-score that IFN-g-secreting Th1-like cells are the most prominent T cell subset in this setting.
B-T Cell Interaction via HLA-DR Promotes AP
Regarding the APCs that induce/support AP, B cells appeared to be particularly interesting candidates, since they upregulate HLA-DR expression (Mohme et al., 2013) and are present in substantial numbers in the AP compartment ( Figures 1B and S3A ) and due to their emerging role in MS (Krumbholz et al., 2012) . Indeed, we noticed a significant correlation of B and T cell AP, whereas other conventional stimuli shifted to B or T cell proliferation, respectively ( Figures 3A, 3B , and S3A). AP of both B and T cells was higher in REM and HLA-DR15 + individuals ( Figures  3A and 3C) . The reduced T cell AP and IFN-g secretion after B cell depletion and physical separation of B from T cells hint at a central role of B cells in triggering and/or sustaining T cell AP via direct cell-cell interaction ( Figure 3D ). We then addressed whether B cells activate and maintain AP CD4 + T cells more efficiently in REM compared to HDs. Autologous co-cultures of EBV-transformed B cells with expanded AP T cells of HLA-DR15 + HDs and REM showed that AP CD4 + T cells are maintained and activated much more efficiently in the absence of an exogenous stimulus in REM than in HDs ( Figures S3B-S3D ).
Given the strong correlation of AP B and T cells, we examined the relationship between AP B and T cells further. AP B cells predominantly show a memory phenotype and increased expression of HLA-DR; i.e., they are in an activated status, when compared to CFSE hi B cells ( Figures 3E and 3F ). Transfer of autologous AP (CFSE dim ) memory B cells led to strong activation and AP of CD4 + T cells in a HLA-DR-dependent manner (Figure 3G) . Based on these observations, we searched for factors that drive AP of memory B cells. Whereas AP of B cells was independent of bystander activation via CD40 ( Figure 3H ), it was almost abrogated by ibrutinib, a selective BTK inhibitor (Figure 3I) . Addition of ibrutinib did not alter the survival of B cells but caused a decrease in HLA-DR expression on B cells accompanied by a drop of T cell AP ( Figure 3I ). BTK is important for B cell receptor signaling, B cell maturation, and proliferation but also other pathways, such as MHC-class II and Toll-like receptor (TLR) signaling (Pal Singh et al., 2018) . Interestingly, BTK inhibitors are in development for several autoimmune diseases including MS (Mullard, 2017) . The role of BTK activation in AP is further supported by phosphorylation of BTK ( Figure 3J ) suggesting that the activation of memory B cells involves BTK signaling and drives AP of CD4 + T cells via interaction with HLA-DR.
Memory B Cells Drive AP of T Helper Cells
B cell depletion with anti-CD20 antibodies very effectively reduces MS relapses suggesting an important role of B cells (E) RNA sequencing data of sorted CFSE hi and CFSE dim (AP) CD4 + T cells (n = 5 REM) for Th1, Th2, and Th17 gene sets, each defined by 17 subset-specific genes. MKI67 served as control transcript for proliferation. The differential expression shows only significantly upregulated genes (log2 >1.0; false discovery rate [FDR] <0.01) in AP CD4 + T cells and is expressed by the z-score based on the reads per kilobase million (RPKM) values. Th gene sets were tested for significance (Fisher test). (F) Distribution of classical Th1 (CXCR3 + CCR6 -), non-classical Th1 (CXCR3 + CCR6 + ), and Th17 (CXCR3 -CCR6 + ) cells in the CFSE hi and CFSE dim compartment, exemplarily shown for AP, MLR, and PHA in one donor and as mean for AP in HDs (n = 9) and REM (n = 13). See also Figure S2 and Table S1 . (Hauser et al., 2008) . The clinical effects of anti-CD20 therapies cannot be explained by reduction of autoantibodies as their main mechanism of action (Hauser et al., 2008; Krumbholz et al., 2012) . B cell depletion may, however, reduce the production of proinflammatory cytokines by B cells, which is increased in MS (Li et al., 2015) , and/or their antigen presenting function via MHC-class II (Molnarfi et al., 2013) . To explore how in vivo alterations of circulating B cells under MS treatments affect AP, we analyzed patients treated with rituximab (RTX), which depletes B cells (Hauser et al., 2008) , natalizumab (NAT), which blocks lymphocyte migration to the brain (Yednock et al., 1992) and increases circulating memory and marginal zone B cells , and fingolimod (FTY), which traps naive and central memory T cells in lymph nodes (Brinkmann et al., 2010) and reduces circulating B cells. As expected, circulating B cells were absent in RTX-treated patients, reduced under FTY and increased under NAT ( Figure 4A ). Consistent with our above in vitro data, RTX strongly reduced AP of T cells and proinflammatory cytokine responses, FTY led to a minor reduction and NAT to a strong increase ( Figures 4B and S4A ). IFN-g production also correlated with the frequency of AP T cells ( Figure 4C ). The strong reduction of in vitro AP T cells raised the question of whether B cell depletion would also affect peripheral T cell numbers in RTX-treated patients in vivo. T cell counts indeed dropped under RTX ( Figure 4D ). Further, we found significantly lower frequencies of activated effector memory CD4 + T cells ex vivo following RTX treatment (Figures 4E and 4F) . Of note, the addition of autologous CD20 + B cells obtained pre-therapy to samples collected after RTX treatment restored CD4 + T cell AP ( Figures S4B-S4E ). Even though depletion of B cells abrogated AP of T cells, PBMCs of RTX-treated patients showed normal numbers of monocytes and mounted normal responses to a recall antigen excluding a general unresponsiveness of T cells (Figures S4F and S4G) .
Naive B cell numbers correlated negatively, while memory and particularly unswitched memory B cells correlated positively with the frequency of AP T cells, suggesting that AP of T cells primarily depends on memory B cells ( Figure 4G ). Indeed, transfer of autologous memory B cells obtained at baseline to samples collected during RTX treatment increased AP and CD4 + T cell activation compared to transfer of naive B cells. This increase was dependent on HLA-DR on memory B cells ( Figure 4H ). In line with this and also the magnitude of AP, we observed lower memory B cell frequencies ex vivo in REL in contrast to an increase following NAT therapy, both in comparison to REM (Figure 4I) . Importantly, memory but not naive B cells promoted AP and CD4 + T cell activation directly upon co-culturing B and T cells alone ( Figure 4J ).
AP T Cells Are Enriched for Brain-Homing Cells
The increase of AP with NAT therapy may not only be due to the increase in peripheral memory B cells but also because NAT traps brain-homing cells in the peripheral blood. This conclusion is supported by the reduced AP during clinical MS relapses, i.e., when pathogenic cells presumably have migrated to the brain, and may explain why MS patients often show strong rebound of disease activity when NAT treatment is stopped (Sorensen et al., 2014) . To examine this issue, we compared the TCR beta chain variable gene (TCRVb) sequences in peripheral AP T cells and in brain lesion-infiltrating T cells of two MS patients ( Figure 5A ; Table  S4 ; Table S5 ), from whom brain lesions (autopsy) or braininfiltrating cells (biopsy) were available (Planas et al., 2015 (Planas et al., , 2018 . In two independent experiments in patient 1, we identified a substantial overlap (17.4%-29.9%) of identical productive TCRVb rearrangements between AP (CFSE dim ) and brain lesions compared with a low overlap (2.6%-4.8%) between non-proliferating T cells (CFSE hi ) and brain lesions (Figures 5B and S5A-S5C). In patient 2, we also found greater overlap between AP T cells and brain-infiltrating cells (7.2%) compared to non-proliferating T cells (1.4%) albeit at a lower percentage ( Figure 5C ). Among the shared TCRVb sequences, we identified approximately two-thirds of the sequences from the AP compartment also in resting CFSE hi cells, yet at much higher frequency in CFSE dim cells ( Figure 5B , left graphs under pie charts). Presumably due to the larger cloneset size in CFSE hi versus CFSE dim cells, we found more brainmatching unique TCRVb sequences in the CFSE hi cells, however, overall at lower frequencies than the shared unique TCRVb sequences in the AP compartment ( Figure 5B , right graphs under pie charts). Interestingly, TCR clonotypes, which we identified in peripheral AP T cells, were among the most clonally expanded in the brain (Figures S5D and S5E; Table S5 ).
Since the clone-set sizes of the different cell compartments differed, and the number of shared TCRVb sequences is influenced by this factor (Zvyagin et al., 2014) (Figure S6A ), we corrected the numbers of shared brain-matching unique productive TCRVb sequences in AP and non-proliferating cells for their Figure S3 and Table S1. clone-set sizes, i.e., the numbers of total unique productive TCRVb sequences. Thereupon, we identified not only a higher overlap of the AP compartment with all brain lesions, but particularly with the highly active brain lesion LIII ( Figure 5D ) (Planas et al., 2015) . In the AP compartment, shared TCR sequences were found in peripheral memory CD4 + and CD8 + T cells (Figure S6B; Table S5 ). Normalization for the number of shared TCRVb sequences showed that AP memory CD4 + T cell clonotypes are preferentially found in the highly active lesion (Figures 5E and S6B) . In contrast and in line with another study (Planas et al., 2018) , brain-matching AP memory CD8 + T cell clonotypes are among those that are more globally expanded in the non-proliferating compartment as well as in all three lesions, indicating that brain-infiltrating memory CD8 + T cells may be recruited by bystander mechanisms.
AP TCCs Recognize Antigens Expressed in MS Brain Tissue and B Cells
An important question is whether AP involves recognition of specific antigens and whether these are presented by B cells. To examine this issue, we generated T cell clones (TCCs) from the AP cells of MS patient 1 (homozygous for HLA-DR15) and show that brain-homing T cells can in principle be obtained efficiently from PBMCs. 6 out of 12 generated CD4 + TCCs were also present in the highly active brain lesion LIII ( Figure 6A ). These AP TCCs showed polyfunctional responses with prominent non-classical Th1 or Th2 phenotypes due to high secretion of IFN-g, GM-CSF, IL-5, and IL-13, respectively, as well as expression of CXCR3 and/or CCR6 ( Figures 6A and S6C ). The strong secretion of Th2 cytokines is consistent with the predominant Th2 phenotype of brain-infiltrating T cells in this patient (Planas et al., 2015) .
We next employed an unbiased approach to identify the target antigen/s of the above TCCs using positional scanning combinatorial peptide libraries and biometrical analysis (Zhao et al., 2001) . TCC14 expanded sufficiently to be tested with the full set of 200 positional scanning library mixtures. After determining its HLA-class II restriction (DRB1*15:01), reactivity against all 200 mixtures was tested and showed positive responses against single or multiple amino acids in each of the 10 positions (Figure 6BI ). Using scoring matrices to summarize the reactivity of TCC14 against the decapeptide library after testing multiple doses, we predicted peptides to be recognized by TCC14 using a transcriptome database from the brain lesions of MS patient 1 ( Figure 6BII ) (Zhao et al., 2001) . 92 sequences were synthesized and tested for recognition by TCC14 based upon their appearance in the top 50 predicted peptides for at least one of the matrices used ( Figure 6BIII ). As we showed previously, there is a good relationship between predicted high ranking and T cell response (Sospedra et al., 2010; Zhao et al., 2001 ) since TCC14 recognized many of the high scoring peptides. Subsequent dose titration experiments with the 33 peptides that gave positive responses, among them peptides from members of the RAS guanyl releasing protein (RASGRP1-4) family, showed that a peptide from RASGRP2 was recognized with high antigen avidity (EC 50 = 0.012 mM) ( Figure 6C ). Recognition of the RASGRP2 peptide by TCC14 resulted in secretion of Th2 cytokines and also of IFN-g ( Figure 6D ). RASGRP1-3 are of particular interest, since they are expressed both in the brain lesion of patient 1, but also in the transcriptome of AP memory B cells ( Figure 6E ). However, proteomic analysis demonstrated high abundance of only RASGRP2 and not of the other RASGRPs in B cells and brain of MS patients ( Figure 6F ; Table S6 ).
RASGRP2 Is Expressed in B Cells and Cortical Gray
Matter and Recognized by Memory T Cells RASGRP2 expression in striatal neurons has been reported (Toki et al., 2001) , and here we demonstrate its wide expression in human cortical gray matter and specifically also in neurons (Figure 7A) . The latter region is of interest in MS since cortical lesions and neurodegeneration have been related to ectopic lymphoid follicles in the meninges (Magliozzi et al., 2007) .
To assess the immunogenicity of RASGRP2 in MS patients, we tested T cell reactivity to overlapping peptides covering RASGRP2 (Table S7 ) by fluorospot in PBMCs of HDs, untreated REM, and NAT-treated MS patients ( Figures S7A and S7B ). We observed a stepwise increase in T cells producing IFN-g and IL-17 with highest numbers in NAT-treated MS patients. Responses were directed against multiple epitopes of RASGRP2. Of particular interest is the high frequency in NAT-treated MS patients indicating that pathogenic cells are trapped in the (J) Sorted naive and memory B cells were co-cultured with autologous CFSE-labeled CD4 + T cells to assess AP and activation of CD4 + T cells after 7 days (mean ± SEM; n = 4 REM; Kruskal-Wallis test). See also Figure S4 and Table S1. Cell 175, 1-16, September 20, 2018 9
Please cite this article in press as: Jelcic et al., Memory B Cells Activate Brain-Homing, Autoreactive CD4 + T Cells in Multiple Sclerosis, Cell (2018), https://doi.org/10.1016/j.cell.2018.08.011 Figure 5 . Peripheral Blood-Derived TCCs Undergoing AP Are Frequently Found in MS Brain Lesions (A) TCRVb repertoire of the AP compartment and TCCs generated thereof were compared with the corresponding brain infiltrate of two MS patients. (B and C) Frequency overlap of unique productive TCRVb sequences in peripheral CFSE hi (red) and CFSE dim (AP, purple) with TCRVb sequences in the MS brain lesions (B; MS patient 1, experiment B) or the brain infiltrate (C; MS patient 2) represented by pie charts. Box-and-whisker plots indicate the distribution and frequency of all TCRVb sequences from the respective peripheral cell compartments. Shared TCRVb sequences in the brain infiltrate that were found also in both (left graph) or uniquely (right graph) in one of the two CFSE compartments are depicted by dots. The number (n) of total unique (gray) and the number as well as frequency overlap of shared TCRVb sequences of the CFSE hi (red) and CFSE dim (purple) compartment are shown. (D and E) Overlap of TCRVb sequences upon normalization of the shared and total clone-set sizes that were compared with each other. The calculated value is given as arbitrary unit (AU) and was performed based on the TCRVb sequences in the clone sets of MS patient 1 and 2 (D), and on the TCRVb sequences that were matching with either peripheral blood memory (CD45RO + ) CD4 + (red) or CD8 + (blue) T cells of MS patient 1 (E). See also Figures S5 and S6 and Tables S4 and S5. (legend continued on next page)
Cell 175, 1-16, September 20, 2018 11 periphery. Consistent with this, RASGRP2 responders almost all showed high AP ( Figure S7C ).
We next examined whether RASGRP2 reactivity is mediated by memory T cells and whether elimination of B cells would help to distinguish AP from reactivity to the RASGRP2 peptides/protein. Depletion of CD45RA-positive cells, which include naive T cells and also B cells, enriched not only for memory T cells but most importantly also depleted the entire B cell lineage ( Figure 7B ). The elimination of B cells reduced the ''background proliferation,'' i.e. AP, over 7 days ( Figure 7C ). Using this methodology, we identified reactivity in TCC14 and all tested CD45RA-depleted PBMCs of NAT-treated MS patients to various RASGRP2 peptide pools, but importantly also to the whole RASGRP2 protein ( Figure 7D ). The latter demonstrates that memory T cells in MS are recognizing also naturally processed and presented RASGRP2 epitopes.
DISCUSSION
Our data indicate that the interaction of B and T cells leads to activation and growth, i.e., AP, which appears to play an important role in the autoimmune response in MS. The study extends our previous findings that myelin-specific T cells can be activated, show TCR signaling, and proliferate upon contact with fully activated dendritic cells and in the absence of exogenously added antigen (Kondo et al., 2001) .
The simple CFSE-based in vitro system demonstrates increased AP in PBMCs in the clinically inactive state of the disease that is driven by memory B cells and is enriched for likely pathogenic, brain-homing effector memory T cells, i.e., cells that can invade an immunoprivileged organ. Clinical observations from anti-CD20 and anti-VLA-4 treatment support the interaction between B and T cells. B cells may thus participate not only in maintaining, but also in creating a pathogenic T cell repertoire in the periphery during REM. Recent data have shown that B cells are involved in thymic selection (Yamano et al., 2015) , and it is conceivable that they shape a T cell repertoire with the propensity to (cross-) react with CNS autoantigens already at this stage. Restimulation and pathogenic differentiation of these T cells may again involve B cells in peripheral secondary lymphoid organs, although the site, where this takes place, is not clear. The demonstration of tertiary lymphoid structures in the meninges of MS patients (Magliozzi et al., 2007) , which are rich in B and T cells and close to cortical lesions, indicates that B-T interactions may also be involved in sustaining inflammation in the CNS. B cell receptor sequencing of antigen-experienced B cells suggests that CNS-homing B cells differentiate in cervical lymph nodes before entering the CNS (Stern et al., 2014) , and Ig class-switched memory B cells exchange between periphery and brain (Palanichamy et al., 2014) . Important questions arising from these observations are: Which is the nature of the self-peptides that activate and/or expand autoreactive CD4 + T cells, and whether the ones leading to activation in the peripheral immune system are identical to those recognized in the brain? Data from many laboratories including ours have shown that peptides from the myelin proteins proteolipid protein (PLP), myelin basic protein (MBP), and myelin oligodendrocyte glycoprotein (MOG) are target antigens in EAE and may also play a role in MS (Goverman, 2009; Sospedra and Martin, 2005) . MOG and full-length PLP are not expressed in immune cells or the thymus, while MBP is, and hence in the case of MOG-and PLP-reactive T cells a mechanism like molecular mimicry and activation by another antigen, e.g., from a pathogen, has been invoked (Wucherpfennig and Strominger, 1995) . Furthermore, a few non-myelin proteins including alpha-B crystallin and transaldolase-H, which are expressed in both lymphoid and CNS cells, may be recognized by T cells of MS patients, indicating that target antigens do not have to be myelin proteins (Sospedra and Martin, 2005) . In our current study, we demonstrate not only that HLA-DR on memory B cells and B cell receptor (BCR) signaling are involved in AP, but further that these cells can express molecules like RASGRPs, which are involved in reduced apoptosis and tumorigenesis of EBV-infected B cells and B and T cell signaling and are crucial for maintaining B-T cell homeostasis (Stone, 2011) . Of note, RASGRPs and particularly RASGRP2 are expressed in the brain as well. The unbiased identification of RASGRP2 as a highavidity target antigen for CD4 + TCC14, which we isolated from peripheral AP T cells and which is clonally expanded in an active brain MS lesion, lends support for a scenario, in which activation of peripheral B cells with upregulation of HLA-DR and expression of antigens like RASGRP2 can then activate and propagate autoreactive CD4 + T cells, which migrate to and induce inflammation in the brain. In this case, the inducing antigen and the target antigen are identical. Important questions concerning how the cortical/neuronal expression pattern of RASGRP2 relates to inflammation in the meninges, perivascular spaces, or brain parenchyma, and how the released protein may be distributed via the CSF, remain to be addressed.
In summary, our data link B and T cells with MS pathogenesis and show that the interactions of these two cell types probably occur in conjunction with the MS-associated DR15 molecules and that B cells may express antigens, which are also upregulated in the brain and recognized by AP CD4 + T cells. We expect that our data will be instrumental for further studies about MS pathomechanisms, as in vitro drug finding platform and to guide the search for the specificity of B and T cells. Furthermore, they provide a plausible explanation for the high efficacy of anti-CD20 therapy in a T cell-mediated disease such as MS. Future studies should address whether AP is influenced by antigen-specific tolerization (Lutterotti et al., 2013) .
(E) Expression level (RPKM) of stimulatory peptide-originating transcripts (e.g. RASGRP1-4) and control transcripts (MOBP, CD19) in the active brain lesion III of MS patient 1 and AP B cells (n = 6 REM). Expression levels under 0.1 or absent were set as 0.1. (F) Proteome analysis of peripheral blood B cells (n = 4 REM) and brain tissue (gray matter, pooled, n = 6 MS). The protein coverage (columns) and spectral counts (numbers) of RASGRP1-4 are depicted as measure for protein abundance. See also Figure S6 and Table S6 .
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: (D) Proliferative responses of CD45RA-depleted PBMCs (NAT; n = 8) and TCC14 to overlapping 15-mer RASGRP2 peptide pools, covering the sequence of RASGRP2 from N (pool 1) to C terminus (pool 9), to the recombinant RASGRP2 protein, vehicle control (DMSO), and a-CD2/CD3/CD28 stimulation after 7 days. Dots represent replicate wells (NAT: mean ± SEM; TCC14: mean ± SEM of 6 replicate wells). Stimulatory index (SI) = ratio of the response of a given well to the mean response of the vehicle control. A SI >2 is considered as positive response. See also Figure S7 and using a harvester machine (Tomtec). Incorporation was measured by b-scintillation counting (Wallac 1450, Perkin-Elmer). Proliferative responses were given as counts per min (cpm).
B cell depletion and transfer
Specific depletion of B cells was performed by depleting CD19 + B cells or CD20 + B cells after CFSE labeling of PBMCs using magnetic microbeads according to the manufacturer's instructions (Miltenyi Biotec) . Co-cultures in transwells (Corning) were used to prevent cell-cell interactions between magnetically isolated CD19 + B cells and autologous PBMCs after CFSE labeling. For post-culture transfer experiments, CFSE hi and CFSE dim B cells were sorted after 7 days of stimulus-free culture using CFSE-labeled PBMCs (150 Mio cells) from RRMS (REM) patients, subsequently incubated with control isotype or HLA-DR-blocking (L243) antibodies (10 mg/ml) for 30 min on ice and then transferred to CFSE-labeled and CD19-depleted autologous PBMCs. FACS analysis of proliferation and activation was then assessed after 7 days of stimulus-free co-culture in AIM-V medium. For B cell transfer experiments in longitudinal samples of rituximab-treated MS patients we isolated either CD20 + , CD27naive or CD27 + memory B cells by separating these B cell subpopulations ex vivo from PBMCs from baseline (pre-therapy) with magnetic microbeads (CD20) or FACS sorting (CD19, CD27), respectively. Isolated CD27naive or CD27 + memory B cells were incubated with control isotype or HLA-DR-blocking (L243) antibodies (10 mg/ml) for 30 min on ice prior to transfer. Following transfer of the B cell subsets to CFSE-labeled autologous PBMCs from time point of rituximab treatment, cells were seeded in AIM-V for 7 days in the absence of exogenous stimulus (AP) as described above and then analyzed by flow cytometry. All conditions in depletion and transfer experiments were performed with at least 6-10 replicate wells.
Primary B-T cell co-cultures
Naive and memory B cells were sorted upon labeling with antibodies against CD19 and CD27 via FACS and subsequently put in AIM-V medium. At the same time autologous PBMCs were labeled with CFSE as described above and used to magnetically isolate untouched CD4 + T cells according to the manufacturer's instructions (Miltenyi Biotec). All cell populations were checked for > 90% (> 95% for sorting) purity in flow cytometry. Isolated CFSE-labeled CD4 + T cells (5x10 4 cells) were cultured either alone, with sorted autologous naive or memory B cells (5x10 4 cells) per well in a 96-well U-bottom microtiter plate in AIM-V in the absence of exogenous stimulus. Following 7 days, cells were analyzed by flow cytometry by staining for live cells, CD4, CD19 and HLA-DR. Each condition was performed with 5 replicate wells.
Expansion of T and B cells
AP cells (CFSE dim ) were sorted after 7 days of PBMC culture (5x10 7 ) in the absence of exogenous stimulus from 5 HLA-DR15+ HD and 5 HLA-DR15+ RRMS (REM) using a FACSAria (BD). Staining with the viability dye 7-AAD (Biolegend) was used to exclude dead cells. The sorted cells were then expanded as bulk populations for one round with 1 mg/ml phytohemagglutinin (PHA, Sigma-Aldrich) and human IL-2 as previously described . Autologous EBV-transformed B cell lines were generated from PBMCs of the HLA-DR15+ individuals using the supernatant of the EBV-producing marmoset B cell line B95-8 and OKT3 antibody as described above.
Cytokine measurement
Supernatants were collected from the wells of cultured CFSE-labeled PBMCs after 7 days. Cytokines were measured with Human T Helper Cytokine Panel LEGENDplex bead-based immunoassay (Biolegend; incl. measurement of 13 human cytokines: IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, IL-17A, IL-17F, IL-21, IL-22, IFN-g and TNF) using flow cytometry according to the manufacturer's instructions. IFN-g ELISA (Biolegend) and GM-CSF ELISA (BD Biosciences) was performed according to the manufacturer's instructions. Heatmaps for cytokine responses were generated using Spice software (NIH, NIAID). For visualization purposes in graphs using a log axis absent values or values below standard range were set as 1.
Ex vivo multicolor staining B and T cell numbers were analyzed before and after rituximab treatment in 179 MS patients (Table S1 ). Whole blood was collected, lysed with IOTest â 3 Lysing Solution (Beckman Coulter) and stained with an antibody mix containing antibodies against CD19 and CD3 (multicolor panel from Beckman Coulter including antibodies against CD45, CD56, CD19 and CD3 and in addition an antibody against CD16 from BD). For the quantification of absolute T and B cell numbers Flow-Count Fluorospheres (Beckman Coulter) with a known concentration were added at an equal volume to the stained sample. Measurements were performed on a Navios (Beckman Coulter) flow cytometer until March 2016 and on an Aquios (Beckman Coulter) flow cytometer after April 2016. The number of cells was calculated as follows: absolute count (cells/ml) = (total number of cells counted / total number of fluorospheres counted) x concentration of flow-count fluorospheres. T cell subtypes and activated T cells were analyzed in 9 RRMS samples before (untreated) and after rituximab therapy (Table S1 ) using a multicolor panel with appropriate antibodies (Key Resources Table) . PBMCs from untreated RRMS (REM) patients used for the in vitro CFSE assay, were stained ex vivo for multiple B cell markers (Key Resources  Table) to distinguish different B cell subsets and to correlate their frequency with the AP of T cells in vitro.
were pooled, Fc-blocked with human IgG and labeled with Live/Dead â Aqua at 4 C and subsequently stained for CD3, CD4 and CD8 on ice (Key Resources Table) . Following fixation and permeabilization with Cytofix/Cytoperm (BD Biosciences), cells were stained with cytokine-specific antibodies (Key Resources Table) in PBS containing saponin (Applichem) and bovine serum albumin (BSA; Roth). Measurement of phosphorylated signaling molecules was performed on CFSE-labeled PBMCs of RRMS (REM) patients at day 7 of stimulus-free culture. After pooling replicate wells, cells were labeled with Live/Dead â Aqua and stained with an antibody against CD3 or CD19 on ice to prevent activation by the antibody. All centrifugation steps as well as buffers were pre-chilled at 4 C. Following wash steps in ice-cold PBS containing 2mM EDTA and 2% FCS, cells were fixed with 2% PFA for 15 min and after centrifugation permeabilized with 90% ice-cold methanol. Finally, the cells were stained with antibodies against phosphorylated epitopes of STAT1, CD3z, ZAP-70 or BTK (Key Resources Table) in PBS containing saponin and BSA. Measurements were performed on an LSR Fortessa Flow Cytometer (BD Biosciences), and data were analyzed with FlowJo (Tree Star).
RNA sequencing
For RNA sequencing analysis of non-proliferating (CFSE hi ) and AP (CFSE dim ) CD3 + CD4 + and CD19 + cells, we labeled 5x10 7 CFSElabeled PBMCs of RRMS (REM) patients at day 7 of unstimulated in vitro culture with Live/Deadâ Aqua and antibodies against CD3, CD4, CD8 and CD19 (Key Resources Table) and subsequently sorted live CFSE hi and CFSE dim cells of CD3 + CD4 + and CD19 + subsets using a FACSAria III (BD Biosciences). Sorted cells were adjusted to the same cell number for CFSE hi and CFSE dim , washed once in PBS, resuspended in Qiazol (QIAGEN) and after a short incubation at room temperature frozen at À80 C. RNA isolation was performed with the PicoPure RNA Isolation kit (Thermo Fisher Scientific) according to the manufacturer's instructions after phenol (Qiazol)/chloroform extraction. In brief, Qiazol preserved sorted cells (10.000 -30.000 cells) were incubated with chloroform and centrifuged for 15 min at 12,000xg at 4 C. The upper aqueous phase was collected and added to an equal volume of 70% ethanol. RNA was then isolated using PicoPure RNA Isolation columns and stored at À80 C until RNA sequencing was performed at the Functional Genomics Center Zurich (FGCZ). RNA integrity and quantity were assessed by capillary electrophoresis using RNA PicoChip on the Agilent Technologies 2100 Bioanalyzer (Agilent Technologies). SMARTer stranded total RNAseq-pico input mammalian kit (Clontech laboratories) was used according to manufacturer's instructions for library generation from 500pg of total RNA obtained from CD4 + T cells. Quantification and quality control of generated libraries were performed on an Agilent Technologies 2100 Bioanalyzer with DNA-specific chip (Agilent Technologies). Uniquely barcoded libraries were pooled in equal molarities (10nM) and further used for cluster generation according to the manufacturer's recommendations using TruSeq SR Cluster Kit v4-cBot-HS (Illumina) and sequenced on the Illumina HiSeq 2500 with single read (1x125bp) approach using the TruSeq SBS Kit v4-HS (Illumina). The raw reads were first cleaned by removing adaptor sequences, trimming low quality ends (four bases from read start and read end), and filtering reads with low quality (phred quality < 20). Sequence alignment and isoform expression quantification of the resulting high-quality reads to the human genome assembly (build GRCh38, ensembl 80 annotations) was performed with the RSEM algorithm (version 1.2.22) (Li and Dewey, 2011) with the option for estimation of the read start position distribution turned on. Genes not present (< 10 counts per gene) in at least 50% of samples from one condition were discarded from further analyses. Differential gene expression analysis between CFSE dim and CFSE hi cell samples was performed using the R/bioconductor package edgeR (Robinson et al., 2010) in which the normalization factor was calculated by trimmed mean of M values (TMM) method. P values were adjusted for multiple testing using the Benjamini-Hochberg procedure. For cluster analysis, a p value < 0.01 was applied. Thresholds log2 fold change > 0.5 and adjusted p values < 0.01 were used for pathway analysis with Ingenuity (QIAGEN).
TCRVb sequencing
In order to separate CFSE hi and CFSE dim cells for TCRVb sequencing, we labeled 5x10 7 PBMCs with CFSE as described above, pooled replicate wells after 7 days of stimulus-free co-culture, stained with the viability dye 7-AAD and subsequently sorted live (7-AAD -) non-proliferating (CFSE hi ) and AP (CFSE dim ) subpopulations using a FACSAria III (BD Biosciences). Sorted cells were washed with PBS and frozen as dry pellets at À80 C. Amplification and sequencing of TCRVb CDR3 were performed on extracted DNA of brain lesions and sorted peripheral blood CFSE hi and CFSE dim subpopulations, derived from culture of CFSE-labeled PBMCs, of two MS patients as well as sorted peripheral blood CD4 + CD45RO + and CD8 + CD45RO + memory T cells of one MS patient using the immunoSEQ Platform (Adaptive Biotechnologies â , Seattle, WA). The immunoSEQ Platform combines multiplex PCR with high throughput sequencing and a sophisticated bioinformatics pipeline for TCRVb CDR3 analysis (Carlson et al., 2013; Robins et al., 2009 ). In the data analysis, we first excluded non-productive TCRVb sequences and CDR3 sequences with less than 4 amino acids, and then recalculated the frequency of the remaining unique productive TCRVb sequences in each sample. Shared unique productive TCRVb sequences between different cloneset samples were identified with the immunoSEQ analyzer 2.0 of Adaptive Biotechnologies â based on identical CDR3 amino acid, V-and J-chain sequence. Normalization of the cloneset sample overlap was performed with the following equation: amount of shared unique productive TCRVb sequences in cloneset sample 1 (M) with cloneset sample 2 (N) divided by the amount of total unique productive TCRVb sequences in cloneset size sample 1 (M) multiplied by the amount of total unique productive TCRVb sequences in cloneset size sample 2 (N) . The result was multiplied by 1000 and depicted as arbitrary unit (AU), based on a previous publication (Zvyagin et al., 2014) .
In order to test reactivity to RASGRP2 in memory T cells, cryopreserved PBMCs (1310 8 cells) of natalizumab-treated MS patients were thawed and afterward depleted for CD45RA-expressing cells using magnetic cell sorting (Miltenyi). 2310 5 CD45RA-depleted PBMCs were seeded per well in X-Vivo medium (10-15 replicate wells per condition) and were either unstimulated, treated with vehicle (DMSO) or pulsed with RASGRP2 peptide pools (final concentration of pool 10 mM) or whole purified RASGRP2 protein (Origene; 0.3 mg/ml). The 15-mer-overlapping peptides covering the whole RASGRP2 protein were organized in 9 peptide pools with 7 peptides per pool covering the sequence of RASGRP2 from N-(pool 1) to C terminus (pool 9) (Table S7 ). a-CD2/CD3/ CD28 beads (Miltenyi) were used as positive control and added to 5 replicate wells at day 4 of PBMC culture. Thymidine incorporation assay was used to measure proliferation responses to RASGRP2 after 7 days. Stimulatory index (SI) was calculated as ratio of peptide or protein stimulation versus vehicle control. SI values > 2 were considered as positive.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses were performed with GraphPad Prism. Multiple comparison analyses were assessed with a non-parametric one-way Kruskal-Wallis test and Dunn's multiple comparisons test. Non-parametric two-tailed Mann-Whitney U test was performed on data with only two groups. Wilcoxon matched-pairs signed rank test was used for analysis of paired samples. Correlation was calculated using Spearman's rank correlation test. P values are reported in the figures and figure legends where significant. Error bars are shown as standard error of the mean (SEM) and are indicated in the figures. Sample sizes were chosen based on previous experience of in vitro experiments (Mohme et al., 2013) . Other quantitative and statistical methods are noted above according to their respective technologies and analytic approaches.
DATA AND SOFTWARE AVAILABILITY
The accession numbers of RNA sequencing data of AP B-and CD4 + T cells reported in this paper are ENA: PRJEB19652 for CD3 + CD4 + cells and ENA: PRJEB23143 for CD19 + cells (https://www.ebi.ac.uk/ena).
TCRVb sequencing results reported in this paper can be accessed on the immuneACCESS database of Adaptive Biotechnologies (https://clients.adaptivebiotech.com/pub/jelcic-2018-cell). Table S1 (A) Cell proliferation measured by CFSE-labeling (CFSE dim ) was compared to thymidine incorporation assay using the same donors and equal amounts of PBMCs and incubating for 7 days in serum-free medium and absence of exogenous stimulus (Spearman's rank correlation test). (B and C) Gating strategy of CFSE-labeled cells after 7 days of AP, analyzed by flow cytometry. (B) Gating on singlets, live-and then on CFSE dim cells including all cell divisions (div.), CFSE mid including 1-2 divisions, CFSE low including more than 2 divisions, or non-proliferating resting cells (CFSE hi ). (C) Exemplary cell subset phenotyping of the CFSE dim , CFSE mid , CFSE low and CFSE hi cell compartment showing increasing HLA-DR expression with increasing proliferation. (D) Frequency of AP T cells (CFSE dim CD3 + ) for each HD (n = 32), untreated RRMS in relapse (REL; n = 18) and RRMS in remission (REM; n = 32) (mean ± SEM; Kruskal-Wallis test). (E) CD4/CD8 ratio in the CFSE dim CD3 + compartment of HD (n = 32) and REM (n = 32) (whiskers: min -max). Dotted line at ratio of 1 indicates equal distribution of CD4 + and CD8 + T cells. (F and G) Ratio of naive/memory cell subset frequency in CFSE dim versus CFSE hi compartment of (F) CD4 + and (G) CD8 + T cells respectively is shown for HD (n = 15) and REM (n = 24) (whiskers: min -max; Mann-Whitney U test). A ratio of 1 (dotted line) indicates an equal proportion of the appropriate T cell subset in the CFSE dim and CFSE hi compartment. T cell subsets: T naive CD45RA + CCR7 + ; T CM CD45RA -CCR7 + ; T EM CD45RA -CCR7 -; T TEMRA CD45RA + CCR7 -.
(legend on next page) Figure S2 . IFN-g Secretion Is Strongly Increased during AP in RRMS (REM) but Is Not the Cause of Increased AP, Related to Figures 1 and 2 and Table S1
(A) A second cohort of HD (n = 14; for PHA n = 10) and REM (n = 14; for PHA n = 12) was used to assess AP (unstimulated) and reactivities to conventional B-(a-IgM) or T cell stimulation with polyclonal/broad (MLR, PHA) or antigen-specific (TTx) activation using CFSE-labeling and subsequent co-culture for 7 days in serum-free medium. Frequency of all proliferating (CFSE dim ) cells for each HD and REM under the different conditions is depicted (mean ± SEM; Mann-Whitney U test). (B) Secretion of Th1 (IL-2, TNF, IFN-g), Th2 (IL-4, IL-5, IL-13) and Th17 (IL-17A, IL-21, IL-22) cytokines in supernatants collected after 7 days of AP (no stimulus), conventional B-(a-IgM) or T cell stimulation with polyclonal (MLR) or antigen-specific (TTx) activation from HD (n = 14) and REM (n = 14; for TTx n = 13) (mean ± SEM; Mann-Whitney U test). (C) Levels of IFN-g and GM-CSF secretion in HLA-DR15and DR15 + HD (DR15-n = 20 and DR15+ n = 12) and REM (DR15n = 15 and DR15 + n = 17; whiskers: min -max). Cytokine measurement was performed with bead-based immunoassay and GM-CSF by ELISA. (D) Frequency of CFSE dim cell population (gray bars) in the presence of blocking IFN-g, blocking GM-CSF or appropriate isotype control antibodies (mean ± SEM; n = 5 REM). Cytokine neutralization (blue line) in supernatant is depicted exemplarily for one of the donors. (A) Proportion of CD3 + and CD19 + cells (pie charts) in the CFSE dim compartment of HD (n = 14; for PHA n = 10) and REM (n = 14; for PHA n = 12) after AP (unstimulated) and reactivities to conventional B-(a-IgM) or T cell stimulation with polyclonal/broad (MLR, PHA) or antigen-specific (TTx) activation using CFSE-labeling and subsequent co-culture for 7 days in serum-free medium. (B-D) Sorted and subsequently expanded (PHA, IL-2) AP cells (CFSE dim ) from DR15 + HD and REM were tested for their reactivity on autologous EBV-transformed B cells. For the co-culture experiments, we incubated 2x10 5 CFSE-labeled expanded bulk T cells either alone or with 5x10 5 irradiated (300 Gy) autologous EBV-transformed B cells in the absence of any stimulus or the presence of blocking HLA-DR (L243) antibody or PHA, respectively. After 72 hours, 4 replicate wells of each condition were pooled and analyzed for survival (live-dead marker) and proliferation (CFSE) by flow cytometry. Cells were gated first on CD4 + T cells to exclude B cells, prior to analysis of live cells and then on proliferating cells. (B) Exemplary dot plots of the different conditions shown for one HD and one REM. (C) Survival and (D) proliferation results of DR15 + HD (n = 5) and REM (n = 5) (mean ± SEM).
(legend on next page) Figure S4 . B Cell Depletion Reduces AP and Proinflammatory Cytokine Response, whereas Response to Control Antigen Remains, Related to Figure 4 and Table S1 (A) Secretion of Th1 (IL-2, IFN-g), Th2 (IL-5, IL-13), Th17 (IL-17A, IL-21) cytokines and GM-CSF in supernatants collected after 7 days of AP from untreated and treated RRMS patients (REM, nihil, black, n = 32; RTX, green, n = 14; NAT, blue, n = 15; FTY, orange, n = 10; mean ± SEM; Kruskal-Wallis test). (B-E) CFSE-labeled PBMCs of MS patients before onset of (M0 = month 0) and after RTX treatment (M3 = 3 months) as well as conditions with deletion and transfer of CD20 + cells from PBMCs before onset of RTX (M0) to autologous PBMCs after RTX therapy (M3) were cultured for 7 days in the absence of exogenous stimulus. Samples were analyzed for the frequency of (B) B cells (C) AP T cells, (D) activated HLA-DR + CD4 + T cells and (E) IFN-g secretion (mean ± SEM; n = 5; Kruskal-Wallis test). (F) Ex vivo frequency of monocytes and B cells in longitudinal RTX MS samples (mean ± SEM; n = 5; Mann-Whitney U test). (G) Response of PBMCs from RTX-treated MS patients in 7-day CFSE assay without antigen or in presence of tetanus toxoid (TTx) as control antigen by assessing frequency of proliferating CFSE dim and proliferating T cells (mean ± SEM; n = 5; Mann-Whitney U test).
(legend on next page) Figure S5 . Similar High-Frequency Overlap of Shared TCRVb Sequences between AP Cells and Brain Lesions in Two Independent Experiments Despite Diverse TCRVb Repertoire, Related to Figure 5 and Tables S4 and S5
(A) Comparison of unique productive TCRVb sequences and their frequencies in CFSE hi and CFSE dim cells from the two independent CFSE experiments A and B of peripheral blood in MS patient 1. (B and C) Overlap of productive TCRVb sequences of the (B) CFSE hi and (C) CFSE dim compartment from peripheral blood with brain infiltrates of three MS lesions in two independent experiments of patient 1. (D and E) Graphs show the frequency of productive TCRVb sequences in the isolated CFSE dim cell population (AP) of MS patient 1 in the two independent experiments (D) A and (E) B. The graph is plotted with the TCRVb-chain against the J-chain families. Red bars indicate TCRVb sequences present in the CFSE dim compartment that match with TCRVb sequences in brain lesions. The boxes refer to the red bars and depict the frequency of shared TCRVb sequences in the CFSE dim compartment as well as their frequency and appearance in the different brain lesions. The data from experiment B (MS patient 1) was used for the analyses in Figure 5 .
(legend on next page) Figure S6 . Proliferating CD4 + CD45RO + T Cells Infiltrate Preferentially the High Active Lesion, whereas CD8 + CD45RO + T Cells Are More Globally Expanded, Related to Figures 5 and 6 and Tables S4 and S5
(A) Correlation of the number of shared unique productive TCRVb sequences in cloneset samples 1 (M) and 2 (N) with the number of unique productive TCRVb sequences in cloneset sample 1 (M) multiplied by the number of unique productive TCRVb sequences in cloneset sample 2 (N), in order to normalize the number of shared TCRVb sequences for the cloneset size (Zvyagin et al., 2014) . Correlations were performed for overall TCRVb sequences and TCRVb sequences that were identified in the peripheral CD4 + CD45RO + or CD8 + CD45RO + T cell compartment (Spearman's rank correlation test). (B) Frequencies of shared unique productive TCRVb sequences in the AP compartment and the brain lesions of MS patient 1 (experiment B). Colors indicate, which TCRVb sequences were also identified in the peripheral CD4 + CD45RO + (green) or CD8 + CD45RO + (blue) T cell compartment. Circles correspond to brainmatching TCRVb sequences which are found in both CFSE hi and CFSE dim cells, and triangles correspond to brain-matching TCRVb sequences only found in CFSE dim cells. The position of the symbols reflects the corresponding frequency of the TCRVb sequence inside the AP compartment or the brain lesion. (C) Brain-homing CD4 + TCCs from the AP compartment of MS patient 1 were analyzed for the expression of the brain-homing receptors CXCR3 and CCR6. Prior to analysis, gates were set on live cells.
(legend on next page) Figure S7 . Th1-Th17 Reactivity to RASGRP2 Is Influenced by AP and Increases Stepwise from HD to REM to NAT, Related to Figures 1, 2, and 7 and Table S7 (A) Fluorospot images in PBMCs with cytokine reactivity (IFN-g and/or IL-17) to the RASGRP2 peptide pool 1, as compared to the vehicle control. The positive control with anti-CD3 stimulation is included for comparison. (B) Fluorospot-based cytokine reactivity in PBMCs from HD (n = 11), REM (n = 9) or RRMS patients treated with NAT (n = 20). Number of IFN-g + , IL17 + and IFNg + IL17 + spots is shown for the negative control (vehicle) and upon stimulation with RASGRP2 peptide pools, covering the sequence of RASGRP2 from N-(pool 1) to C terminus (pool 9). Each condition was performed for each donor in duplicate wells. The dots represent the response in a given well. Mean ± SEM is shown with red bars while the red dotted line depicts the mean + 3x standard deviation of the vehicle control. The latter is considered as threshold for positive responses. (C) The results from fluorospot were compared to the degree of AP measured by the CFSE assay in the same individuals (incl. HD and REM; n = 16). Number of IFN-g + , IL17 + and IFN-g + IL17 + spots is shown for the negative control (vehicle) and upon stimulation with RASGRP2 peptide pools. Orange dots correspond to samples with low AP (< 0.9% CFSE dim ), while blue dots correspond to samples with high AP (> 0.9% CFSE dim ).
